TXG

10X Genomics

$54.99

-5.50%
Nov 16, 2026
Bobby Quantitative Model
10x Genomics is a life science technology company that designs and sells integrated instruments, consumables, and software for single-cell and spatial biology research, spanning its Chromium, Visium, and Xenium platforms used by academic, translational, and biopharma customers worldwide. The company is a category-defining platform player in spatial and single-cell genomics, holding a leading position in a niche but rapidly evolving tooling market where differentiation rests on assay resolution, throughput, and an installed-base-driven razor-and-blade consumables model. The current investor narrative has shifted decisively from a multi-year post-COVID digestion story toward a recovery-and-re-rating thesis, with the stock up roughly 256% over the past year as investors price in stabilization of instrument placements, consumables-led growth, and a credible path toward profitability. Debate now centers on whether the recent revenue inflection is durable, how Xenium spatial launches scale against emerging competitors, and whether the company can convert its 69% gross margin and positive free cash flow into sustained earnings power, with a recent patent verdict win over Parse Biosciences adding a legal-overhang subplot that the market initially greeted with skepticism.

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN

Analysis
Moderna

Moderna

MRNA

Analysis
BeOne Medicines Ltd. American Depositary Shares

BeOne Medicines Ltd. American Depositary Shares

ONC

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis

BobbyInvestment Opinion: Should I buy TXG Today?

Rating: Hold, with a constructive bias. The core thesis is that 10x Genomics is a category-leading spatial and single-cell platform whose operating trajectory (gross margin up to 74.95%, TTM FCF of $93.77 million, net loss narrowing from -$27.47M to -$19.43M year-over-year) is improving faster than its top line (Q3 2026 revenue of $150.67M, +1.12% YoY), leaving the stock fairly-to-richly valued until consumables pull-through proves durable. The consensus 'buy' label is soft: 6 Buy, 11 Hold, 0 Sell across 14 analysts, a recommendation mean of 2.35, and an average target of $68.14 implying only +17.1% upside from $58.19.

Supporting evidence is mixed but tilts modestly positive on quality and negative on price. Positives: gross margin of 74.95% in Q3 2026 versus 68.1% in Q4 2025 and 67.3% in Q3 2025; positive TTM free cash flow of $93.77M with quarterly FCF of $14.86M/$15.39M/$24.52M across Q3/Q2/Q1 2026; a fortress balance sheet with $526.19M cash, current ratio of 4.46, and debt-to-equity of 0.198; and a PEG of 0.61 that is attractive only if the forward EPS of $0.305 materializes. Negatives: PS of 3.17x looks cheap versus the industry blend but EV/Sales of 11.57x and EV/EBITDA of 439.6x are demanding for a ~1% grower, the forward PE of 671.4x prices a profitability inflection that has not appeared, and the stock is up 255.9% over one year while down 20.4% in the past month (relative strength -18.1 points versus SPY).

Three risks could invalidate the thesis: revenue staying at ~1% growth with consumables ($134.3M of $150.2M product-and-service revenue) failing to reaccelerate; multiple compression from 11.57x EV/Sales toward the $50 analyst low (-14%) or the $40s (-30%) if the $55-58 support zone breaks; and dilution, with shares outstanding rising from 121.6M in Q4 2024 to 130.8M in Q3 2026 alongside $23.1M of quarterly stock-based compensation. This Hold would upgrade to Buy on evidence of revenue growth above 5% with gross margin holding above 74%, or on a pullback toward $50 that restores risk/reward; it would downgrade to Sell if growth turns negative or gross margin slips below 70%. Verdict: fairly valued to modestly rich relative to current growth, but cheap relative to its own history (PS of 3.17x versus 12.5x at year-end 2025 and 78.4x in the Q3 2026 historical snapshot), so the debate is about timing the inflection, not about the asset quality.

Sign up to view all

TXG 12-Month Price Forecast

The forward view is balanced: the operating trajectory is genuinely improving, with gross margin at 74.95%, positive TTM free cash flow of $93.77M, and a net loss narrowing from -$27.47M to -$19.43M year-over-year, but the top line at +1.12% growth cannot yet support an 11.57x EV/Sales and 671.4x forward PE. The stock's 255.9% one-year gain has already priced much of the recovery, and the recent 20.4% pullback with -18.1 points of relative weakness shows how quickly that re-rating can unwind given beta of 2.03. Analyst sentiment is conviction-light, with 11 of 14 on Hold and a $50-to-$100 target spread that signals real disagreement about Xenium's competitive trajectory. I would upgrade to bullish on a quarter showing revenue growth above 5% with gross margin holding above 74%, or on a pullback toward the $50 analyst low that restores risk/reward; I would downgrade to bearish if growth turns negative or gross margin slips below 70%.

Historical Price
Current Price $54.99
Average Target $67.00
High Target $100.00
Low Target $40.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on 10X Genomics's 12-month outlook, with a consensus price target around $68.14 and implied upside of +23.9% versus the current price.

Average Target

$68.14

17 analysts

Implied Upside

+23.9%

vs. current price

Analyst Count

17

covering this stock

Price Range

$50 - $100

Analyst target range

Buy
6 (35%)
Hold
11 (65%)
Sell
0 (0%)

Coverage is solid with 14 analysts, and the distribution leans cautiously constructive: 6 Buy, 11 Hold, and 0 Sell, yielding a consensus recommendation of "buy" but a recommendation mean of 2.35 (where 1 is strong buy and 5 is strong sell), indicating the average stance is closer to neutral than the headline label suggests. The average target price is $68.14, which against the current price of $58.19 implies roughly +17.1% upside to consensus. Sentiment is therefore best described as moderately bullish but conviction-light, with the large Hold contingent reflecting analyst hesitation about the durability of the growth recovery and the path to profitability.\n\nThe target range is wide, from a low of $50.00 to a high of $100.00, a spread of 100% that signals meaningful disagreement and high uncertainty about the company's trajectory. The high target of $100.00 implies roughly +72% upside and would require multiple expansion alongside accelerating consumables growth and a clear margin inflection toward profitability, essentially a full re-rating back toward the 52-week high. The low target of $50.00 implies about -14% downside and likely prices in continued ~1% revenue growth, margin compression from competitive pressure in spatial biology, and a delayed path to GAAP profitability. Institutional ratings show a stable-to-cautious pattern, with recent actions from Barclays (Overweight), JP Morgan (Neutral), Citigroup (Neutral), UBS (Neutral), and Stifel (Buy) all reaffirming existing stances rather than upgrading or downgrading, suggesting analysts are in a wait-and-see posture pending evidence of a durable revenue reacceleration. The wide spread and heavy Neutral tilt argue for treating the consensus target as a soft signal rather than a high-conviction price objective.

Drowning in data?

Find the real signal!

Bulls vs Bears: TXG Investment Factors

The bear case currently has stronger near-term evidence: revenue growth of 1.12% is nowhere near what an 11.57x EV/Sales multiple requires, the stock has broken down 20.4% in a month with -18.1 points of relative weakness, and 11 of 14 analysts sit on Hold. The bull case rests on genuinely improving fundamentals — gross margin at 74.95%, TTM FCF of $93.77 million, $526 million of cash, and a narrowing net loss — which argue the trough is in even if the inflection is delayed. The single most important tension is whether consumables pull-through from the installed base can reaccelerate revenue from ~1% toward high single digits; if it does, the compressed 3.17x PS versus historical levels (78.4x in Q3 2026, 12.5x at year-end 2025) offers substantial re-rating room, but if ~1% proves the new normal, the forward multiple is unsupportable. Net-net, this is a high-beta recovery story where the operating trajectory is improving faster than the top line, leaving the stock fairly-to-richly valued pending proof of durable growth.

Bullish

  • Massive relative strength vs. market: TXG is up 255.9% over the trailing year and 250.1% YTD versus SPY's 12.3% and 10.6%, producing relative strength of +243.6 and +239.5 percentage points respectively. Even after the recent 20.4% one-month pullback, the 6-month change remains +174.5%, confirming the primary trend is still decisively upward.
  • Gross margin expanding toward 75%: Q3 2026 gross margin reached 74.95%, up from 70.4% in Q1 2026 and 68.1% in Q4 2025, driven by favorable consumables mix and cost discipline. For a life-science tools company this is best-in-class and provides a wide cushion to absorb R&D and SG&A as revenue scales.
  • Positive free cash flow and fortress balance sheet: TTM free cash flow is $93.77 million, with quarterly FCF of $14.86M in Q3, $15.39M in Q2, and $24.52M in Q1 2026. Cash stands at $526.19 million against a debt-to-equity of just 0.198 and a current ratio of 4.46, meaning the company funds itself internally with no financing dependency.
  • Losses narrowing with operating leverage emerging: Net loss improved from -$27.47 million in Q3 2025 to -$19.43 million in Q3 2026, and operating margin improved from -21.6% to -10.7% over the same period. EBITDA loss narrowed from -$15.95 million to -$8.97 million, showing the cost structure is beginning to lever as gross profit grows.

Bearish

  • Revenue growth stalled at ~1%: Q3 2026 revenue of $150.67 million grew just 1.12% year-over-year, and revenue has oscillated between roughly $150 million and $166 million for several quarters. The reacceleration the bull thesis depends on has not materialized, and the $150.67M print is actually below Q2 2025's $172.91 million.
  • Valuation demands a profitability inflection: With a trailing PE of -46.6x and a forward PE of 671.4x against consensus forward EPS of just $0.305, the market is pricing a dramatic earnings inflection from near-zero. EV/Sales of 11.57x and EV/EBITDA of 439.6x are demanding for a ~1% grower and leave little room for execution error.
  • Acute near-term distribution and momentum break: The stock is down 20.4% over the past month versus SPY's -2.26%, a relative-strength gap of -18.1 points, and sits 43% below its 52-week high of $102.81. With a beta of 2.03 and a max drawdown of -40.6%, the recent weakness shows how violently the name can unwind after a 256% run.
  • Analyst conviction is thin: Despite a 'buy' headline consensus, the recommendation mean of 2.35 reflects 11 Hold ratings against only 6 Buys and zero Sells. Recent actions from JP Morgan, Citigroup, and UBS were all Neutral reaffirmations, signaling analysts are in wait-and-see mode rather than accumulating conviction.

TXG Technical Analysis

TXG is in a powerful, sustained uptrend that has dramatically reversed a prior downtrend, with the stock up 255.9% over the trailing year and 250.1% year-to-date versus a SPY gain of just 12.3% and 10.6% respectively. At a current price of $58.19, the stock sits at roughly 49.4% of its 52-week range of $15.18 to $102.81, meaning it has surrendered more than half of its peak gains despite the enormous annual advance. This positioning is best characterized as a high-momentum name that has entered a corrective phase within a larger uptrend, rather than a stock near highs (overextended) or near lows (falling knife). The 52-week high of $102.81, set in early October, remains a distant 43% above the current price, underscoring how sharp the recent pullback has been relative to the annual trajectory.\n\nShort-term momentum has decelerated sharply and now diverges from the longer-term trend. The stock is down 20.4% over the past month while SPY fell only 2.26%, producing a relative-strength reading of -18.1 percentage points, a clear signal of acute near-term underperformance and distribution. Yet the 3-month change remains positive at +3.7% and the 6-month change is a staggering +174.5%, confirming that the one-month weakness is a pullback within a much stronger intermediate and long-term advance rather than a trend reversal. This divergence, where the 1-month trend conflicts with the 1-year trend, typically signals either mean reversion after an overextended run or a temporary consolidation; the fact that the 3-month figure is still positive argues for the latter. The stock's beta of 2.03 confirms it is roughly twice as volatile as the market, amplifying both the upside and the recent drawdown.\n\nKey technical levels are well defined: support sits near the 52-week low of $15.18, with a more relevant near-term floor around the $55-58 zone where the stock has recently stabilized, while resistance is anchored at the $102.81 52-week high, with intermediate resistance near the $80-90 area that capped the October rally. A breakout above the $80-90 band would signal renewed institutional accumulation and a resumption of the primary uptrend, whereas a breakdown below the $55 support would raise the risk of a deeper retracement toward the $40s and undermine the recovery thesis. The maximum drawdown of -40.6% over the period illustrates the stock's capacity for violent swings, and with a beta of 2.03, position sizing must account for roughly double the market's volatility, making stop-loss discipline and smaller position weights prudent for risk management.

Beta

2.03

2.03x market volatility

Max Drawdown

-43.7%

Largest decline past year

52-Week Range

$15-$103

Price range past year

Annual Return

+246.1%

Cumulative gain past year

PeriodTXG ReturnS&P 500
1m-21.3%-3.0%
3m-1.2%-3.6%
6m+129.3%-0.2%
1y+246.1%+10.1%
ytd+230.9%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

TXG Fundamental Analysis

Revenue has stabilized at a low-growth plateau rather than accelerating. The most recent quarter (Q3 2026) delivered $150.67 million in revenue, up just 1.12% year-over-year, a marked deceleration from the $172.91 million reported in Q2 2025 and only marginally above the $149.00 million in Q3 2025. The multi-quarter trend shows revenue essentially flat, oscillating between roughly $150 million and $166 million across the last several quarters, indicating the post-pandemic digestion has bottomed but a reacceleration has yet to materialize. Consumables dominate the mix at $134.3 million of the $150.2 million product-and-service total, while instruments contribute only $6.86 million and services $9.03 million, confirming that growth is consumables-dependent and highly sensitive to utilization of the installed base rather than new instrument placements. The investment case therefore hinges on whether spatial and single-cell consumables pull-through can reaccelerate growth from this ~1% base.\n\nThe company remains unprofitable on a GAAP basis, though losses are narrowing. Q3 2026 net income was -$19.43 million (a -12.9% net margin) on gross profit of $112.93 million, a healthy 74.95% gross margin that actually expanded from 70.4% in Q1 2026 and 68.1% in Q4 2025, reflecting favorable product mix and cost discipline. Operating income was -$16.06 million (a -10.7% operating margin), and EBITDA was -$8.97 million, with the gap to net income driven by $9.5 million of D&A and $23.1 million of stock-based compensation. The trajectory is encouraging: net loss improved from -$27.47 million in Q3 2025 to -$19.43 million in Q3 2026, and gross margin has climbed steadily, suggesting operating leverage is beginning to emerge even as R&D remains elevated at $52.9 million. For a life-science tools company, a ~75% gross margin is strong and typical of high-value consumables, but the persistent GAAP losses reflect heavy R&D and SG&A investment that must eventually be absorbed.\n\nThe balance sheet is a clear strength, providing ample runway. Cash at the end of Q3 2026 stood at $526.19 million, up from $473.97 million at year-end 2025, and the current ratio is a robust 4.46 with a debt-to-equity ratio of just 0.198, indicating minimal leverage and substantial liquidity. Free cash flow is positive and improving, with TTM FCF of $93.77 million and quarterly FCF of $14.86 million in Q3 2026, $15.39 million in Q2, and $24.52 million in Q1, demonstrating the business now generates cash internally to fund operations. ROE of -5.47% and ROA of -3.93% remain negative but are modest, consistent with a company that is near breakeven on a cash basis despite GAAP losses. The combination of a fortress balance sheet, positive FCF, and low leverage means financial risk is low and the company does not depend on external financing, though the gap between positive FCF and negative net income is largely explained by $23.1 million in quarterly stock-based compensation, a real dilution cost investors should monitor.

Quarterly Revenue

$150667000.0B

2026-09

Revenue YoY Growth

+1.1%

YoY Comparison

Gross Margin

75.0%

Latest Quarter

Free Cash Flow

$93771000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Consumables
Instruments
Licensing And Royalty Revenue
Product And Service Revenue
Service

Open an Account, get $2 TSLA now!

Valuation Analysis: Is TXG Overvalued?

Because net income is negative (TTM EPS of -$0.02 and a trailing PE of -46.6x), the PE ratio is not meaningful, so the primary metric selected is the price-to-sales ratio, supported by EV/Sales. TXG trades at a PS of 3.17x and an EV/Sales of 11.57x, while the forward PE of 671.4x reflects the market's expectation that earnings will inflect sharply from near-zero toward the consensus forward EPS of $0.305. The enormous gap between the negative trailing PE and the triple-digit forward PE signals that the market is pricing in a dramatic profitability inflection rather than current earnings, making the valuation highly sensitive to execution on margins.\n\nRelative to the broader Biotechnology industry, TXG's 3.17x PS appears modest, but this comparison is distorted because the industry average blends pre-revenue clinical-stage names with profitable tools companies; on a more apples-to-apples basis against high-margin life-science tools peers, a ~3x sales multiple for a ~1% grower is not obviously cheap. The EV/Sales of 11.57x and EV/EBITDA of 439.6x are far more demanding and reflect the depressed EBITDA base, while the PEG ratio of 0.61 is attractive only if the assumed growth materializes. The premium embedded in the forward multiples is justified only by a credible reacceleration in consumables growth and margin expansion toward breakeven; absent that, the valuation carries downside risk.\n\nHistorically, TXG's PS ratio has compressed dramatically from nosebleed levels: it was 78.4x in Q3 2026 per the historical ratios data (reflecting a much smaller revenue base and higher price at that snapshot), 33.0x in Q2 2026, 18.1x in Q1 2026, and 12.5x at year-end 2025, versus the current 3.17x. This places the stock near the bottom of its own historical valuation band, which could signal either a compelling value opportunity or persistent fundamental deterioration and de-rating. The price-to-book ratio of 2.56x is likewise near multi-year lows compared with 14.1x in Q3 2026 and 6.0x in Q2 2026, reinforcing that the market has repriced the company sharply lower on a per-unit-of-sales and per-unit-of-book basis. The interpretation hinges on whether the ~1% revenue growth is a trough that inflects higher (value opportunity) or a new normal (justified de-rating).

PE

-46.6x

Latest Quarter

vs. Historical

N/A

5-Year PE Range 17x~59x

vs. Industry Avg

29.3x

Industry PE ~29.3x*

EV/EBITDA

439.6x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on a revenue base that has stopped growing while costs remain fixed and elevated. Q3 2026 revenue of $150.67 million grew only 1.12% year-over-year, and the mix is dangerously consumables-dependent — $134.3 million of the $150.2 million product-and-service total comes from consumables, with instruments at just $6.86 million. R&D of $52.9 million plus SG&A of $76.1 million consumed $129.0 million of operating expense against $112.9 million of gross profit, producing a -$16.06 million operating loss and -$19.43 million net loss. The gap between positive TTM FCF of $93.77 million and negative net income is largely explained by $23.1 million of quarterly stock-based compensation, and share count has climbed from 121.6 million to 130.8 million since Q4 2024, so cash generation is being partly offset by dilution. Any further deceleration in consumables utilization would pressure the 74.95% gross margin that currently absorbs these costs. Market and competitive risks are dominated by valuation compression and spatial-biology competition. At 11.57x EV/Sales and 439.6x EV/EBITDA for a ~1% grower, the multiple embeds a profitability inflection (forward EPS of $0.305 against a 671.4x forward PE) that has not yet appeared in the P&L, and the stock's beta of 2.03 means it amplifies any market or sector rotation roughly twofold. The 100% spread between the $50 low and $100 high analyst targets signals genuine disagreement about Xenium's trajectory against emerging spatial competitors, and the recent patent verdict win over Parse Biosciences — a $4.8 million award that was met with a 5% stock decline — shows the market is discounting legal wins while remaining alert to litigation costs. With 11 of 14 analysts on Hold and a recommendation mean of 2.35, there is limited sell-side buffer if sentiment turns. The worst-case scenario is a growth stall combined with multiple compression: revenue stays at ~1% growth, Xenium loses share to competitors, the forward earnings inflection slips, and the stock de-rates back toward its 52-week low of $15.18 — a decline of roughly -74% from the current $58.19. A more realistic adverse path is a retest of the $50 analyst low target, about -14%, or a deeper retracement into the $40s (roughly -30%) if the $55-58 support zone breaks, consistent with the stock's demonstrated -40.6% max drawdown. Given beta of 2.03, position sizing should assume drawdowns of 30-40% are entirely plausible in a risk-off tape.

FAQ

Ranked by severity: first, growth and valuation risk — revenue grew only 1.12% YoY to $150.67 million while the stock trades at 11.57x EV/Sales and 671.4x forward PE, so a stall or negative print would likely force multiple compression toward the $50 analyst low (-14%) or the $40s (-30%). Second, competitive risk in spatial biology, where Xenium faces emerging rivals and consumables — $134.3 million of the $150.2 million product-and-service total — are the growth engine, making installed-base utilization the swing factor. Third, market and volatility risk: beta of 2.03 and a -40.6% max drawdown mean a risk-off tape amplifies losses, as shown by the -20.4% one-month move versus SPY's -2.26% (-18.1 points of relative weakness). Fourth, dilution and profitability risk: $23.1 million of quarterly stock-based compensation bridges positive free cash flow to a -$19.43 million net loss, and shares outstanding have risen from 121.6 million to 130.8 million since Q4 2024.

The base case carries 55% probability with a $62-$72 target range, assuming revenue growth of 1-5%, gross margin of 72-75%, forward EPS near $0.305, and no major litigation costs beyond Parse Biosciences — essentially a holding pattern around the $68.14 analyst average. The bull case at 20% probability targets $85-$100, requiring revenue growth above 5%, Xenium consumables scaling, gross margin at or above 74.95%, and analyst upgrades from the 11 Hold-rated firms. The bear case at 25% probability targets $40-$50, driven by negative growth, gross margin below 70%, and multiple compression amplified by beta of 2.03. The base case is most likely because the operating trajectory is improving (net loss narrowed from -$27.47 million to -$19.43 million YoY) even as the top line lags; the key assumption is that consumables stabilize rather than reaccelerate sharply.

The answer depends on the metric. On price-to-sales of 3.17x, TXG looks cheap versus its own history — 12.5x at year-end 2025 and 78.4x in the Q3 2026 historical snapshot — and versus the blended Biotechnology industry average, though that benchmark is distorted by pre-revenue clinical names. On EV/Sales of 11.57x and EV/EBITDA of 439.6x, the stock is expensive for a company growing revenue 1.12%, and the 671.4x forward PE against consensus EPS of $0.305 prices a profitability inflection that has not appeared. The trailing PE of -46.6x is not meaningful given the -$0.02 TTM EPS. Net-net, the market is paying a fair-to-modestly-rich price relative to current growth but a discount relative to the company's own valuation history, implying investors expect consumables pull-through to reaccelerate revenue and margins to lever toward breakeven; if growth stays near 1%, the multiple is unsupportable.

The risk/reward is balanced rather than compelling at $58.19. Upside to the $68.14 average analyst target is about +17.1%, and the $100 high target implies +72%, but the $50 low target implies -14% and a retest of the $40s would mean roughly -30%. The fundamental quality is real — 74.95% gross margin, $93.77 million TTM free cash flow, $526.19 million cash, current ratio of 4.46 — yet revenue growth of just 1.12% YoY leaves the 11.57x EV/Sales and 671.4x forward PE exposed to any disappointment. Analyst conviction is thin, with 11 of 14 ratings on Hold and a recommendation mean of 2.35 despite the 'buy' headline. It is a reasonable buy only for risk-tolerant investors with a multi-year horizon who want a high-beta (2.03) recovery option and can size the position for a 30-40% drawdown; it is not a good buy for capital-preservation or income-oriented portfolios.

TXG is better suited to a long-term, multi-year holding than to short-term trading, though its volatility cuts both ways. The company is in a late-stage recovery from post-pandemic digestion, with revenue flat near $150 million for several quarters, gross margin expanding to 74.95%, positive TTM free cash flow of $93.77 million, and no dividend (payout ratio of 0), so returns depend entirely on price appreciation and the timing of a profitability inflection. Beta of 2.03, a -40.6% max drawdown, and a -20.4% one-month swing against SPY's -2.26% make short-term positioning treacherous without tight risk controls. Earnings visibility is limited — 11 of 14 analysts are on Hold with a $50-$100 target spread — so a minimum holding period of 18-24 months is reasonable to span at least two earnings cycles and give the consumables thesis time to prove out. Traders could work the $55-58 support and $80-90 resistance band, but that is a tactical overlay, not the core case.